Bipartisan congressional lawmakers have introduced a bill to promote research into the therapeutic potential of certain psychedelics in the treatment of serious mental health conditions experienced by military veterans. Reps. Jack Bergman (R-MI) and Lou Correa (D-CA), co-chairs of the Congressional Psychedelics Advancing Therapies (PATH) Caucus, filed the “Expanding Veterans’ Access to Emerging Treatments Act” earlier this month. The proposal directs the U.S. Department of Veterans Affairs (VA) to carry out clinical trials investigating the therapeutic efficacy of “innovative treatments and emerging therapies”—including psychedelics such as ibogaine, 5-MeO-DMT, ketamine and psilocybin. “Many conditions, such as chronic pain, post-traumatic stress disorder, and substance use disorders, continue to challenge the veteran community amid a lack of new innovative treatments and emerging therapies,” the legislation states. In July, for example, the VA secretary touted his role in promoting psychedelics access for veterans with serious mental health conditions, saying he “opened that door probably wider than most ever thought” was possible.